Trimeris, Inc.
Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials.
Contact Details
Office Address
Trimeris, Inc.
2530 Meridian Parkway, 2nd Floor
Durham, NC, USA 27713
Phone: (919) 806-4682
Fax: (919) 806-4770
Executives
Chief Exec. Officer, Pres and Director
Mr. Martin A. Mattingly Pharm.D.
Chief Financial Officer
Mr. Andrew L. Graham
.webp)
.webp)
.webp)
.webp)
.webp)
